LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

81.83 0.59

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

80.72

Max

83.05

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelnas, tenkantis vienai akcijai

-0.613

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+3.71% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

13B

Ankstesnė atidarymo kaina

81.24

Ankstesnė uždarymo kaina

81.83

Naujienos nuotaikos

By Acuity

34%

66%

101 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-03 23:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

2025-12-03 23:14; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5 Million

2025-12-03 22:01; UTC

Pagrindinės rinkos jėgos

Costco Wholesale Reports Higher Monthly Sales

2025-12-03 21:38; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

2025-12-03 23:59; UTC

Rinkos pokalbiai

Australian Coal Prices Seen Having Recovered Well -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

2025-12-03 23:13; UTC

Rinkos pokalbiai

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

2025-12-03 23:10; UTC

Uždarbis

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

2025-12-03 23:08; UTC

Rinkos pokalbiai

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

2025-12-03 23:06; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

2025-12-03 22:59; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5M

2025-12-03 22:45; UTC

Rinkos pokalbiai

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

2025-12-03 22:20; UTC

Uždarbis

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

2025-12-03 22:19; UTC

Uždarbis

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

2025-12-03 22:17; UTC

Uždarbis

Salesforce Working to Add Voice to Agentforce, CEO Says

2025-12-03 22:16; UTC

Uždarbis

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

2025-12-03 22:15; UTC

Uždarbis

Salesforce CEO: Agentforce ARR Was $540M in 3Q

2025-12-03 22:10; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

2025-12-03 22:09; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

2025-12-03 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-03 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-03 21:49; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:23; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

2025-12-03 21:19; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:06; UTC

Uždarbis

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

2025-12-03 21:04; UTC

Uždarbis

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

2025-12-03 21:04; UTC

Uždarbis

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

2025-12-03 21:03; UTC

Uždarbis

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

3.71% į viršų

12 mėnesių prognozė

Vidutinis 84.33 USD  3.71%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

14

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

101 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat